Autopsy report · NCT03287050
Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
Cause of deathOther
“due to changing therapeutic landscape in metastatic bladder cancer and lack of radiation/immunotherapy systemic synergy in other malignancies”
Life of this trial
- Registered 4 months before it started.
- Ran for about 2 years 10 months before it stopped.
- 6 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of Michigan Rogel Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Urothelial Carcinoma
- Interventions
- Pembrolizumab; SBRT
- Participants
- 6
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.